WO2002055665A3 - Methods to identify compounds useful for the treatment of proliferative and differentiative disorders - Google Patents

Methods to identify compounds useful for the treatment of proliferative and differentiative disorders Download PDF

Info

Publication number
WO2002055665A3
WO2002055665A3 PCT/US2002/000311 US0200311W WO02055665A3 WO 2002055665 A3 WO2002055665 A3 WO 2002055665A3 US 0200311 W US0200311 W US 0200311W WO 02055665 A3 WO02055665 A3 WO 02055665A3
Authority
WO
WIPO (PCT)
Prior art keywords
ubiquitin ligases
disorders
treatment
proliferative
novel
Prior art date
Application number
PCT/US2002/000311
Other languages
French (fr)
Other versions
WO2002055665A2 (en
Inventor
Michele Pagano
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Priority to AU2002243477A priority Critical patent/AU2002243477B2/en
Priority to IL15677802A priority patent/IL156778A0/en
Priority to CA002433795A priority patent/CA2433795A1/en
Priority to NZ527047A priority patent/NZ527047A/en
Priority to JP2002556716A priority patent/JP4121854B2/en
Priority to EP02708966A priority patent/EP1352080A4/en
Publication of WO2002055665A2 publication Critical patent/WO2002055665A2/en
Publication of WO2002055665A3 publication Critical patent/WO2002055665A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11,FBP12,FBP13,FBP14,FBP15,FBP16,FBP17,FBP18,F FBP19,FBP20,FBP21,FBP22,FBP23,FBP24, and FBP25, transgenic m ice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulates activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.
PCT/US2002/000311 2001-01-05 2002-01-07 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders WO2002055665A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2002243477A AU2002243477B2 (en) 2001-01-05 2002-01-07 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
IL15677802A IL156778A0 (en) 2001-01-05 2002-01-07 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
CA002433795A CA2433795A1 (en) 2001-01-05 2002-01-07 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
NZ527047A NZ527047A (en) 2001-01-05 2002-01-07 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
JP2002556716A JP4121854B2 (en) 2001-01-05 2002-01-07 Methods for identifying compounds useful in the treatment of proliferative and differentiated diseases
EP02708966A EP1352080A4 (en) 2001-01-05 2002-01-07 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26017901P 2001-01-05 2001-01-05
US60/260,179 2001-01-05

Publications (2)

Publication Number Publication Date
WO2002055665A2 WO2002055665A2 (en) 2002-07-18
WO2002055665A3 true WO2002055665A3 (en) 2002-09-26

Family

ID=22988099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000311 WO2002055665A2 (en) 2001-01-05 2002-01-07 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders

Country Status (9)

Country Link
US (7) US20020123082A1 (en)
EP (1) EP1352080A4 (en)
JP (1) JP4121854B2 (en)
AU (1) AU2002243477B2 (en)
CA (1) CA2433795A1 (en)
IL (1) IL156778A0 (en)
NZ (1) NZ527047A (en)
WO (1) WO2002055665A2 (en)
ZA (1) ZA200305230B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088846A1 (en) * 1998-08-28 2006-04-27 Michele Pagano Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
US20050079558A1 (en) * 1998-08-28 2005-04-14 New York University Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
JP2005523280A (en) * 2002-02-12 2005-08-04 カイロン コーポレイション Cks1 inhibitor
US20060089321A1 (en) * 2002-02-12 2006-04-27 Walter Annette O Cks1 inhibitors
US7037936B2 (en) 2002-06-17 2006-05-02 Signal Pharmaceuticals, Llc. Compounds useful for the treatment of cancer, compositions thereof and methods therewith
GB0309116D0 (en) * 2003-04-22 2003-05-28 Univ London Target for cancer therapy and drug discovery
EP1810008A4 (en) * 2004-10-15 2008-09-10 Signal Pharm Llc P27 ubiquitination assay and methods of use
WO2007139820A2 (en) * 2006-05-24 2007-12-06 Albert Einstein College Of Medicine Of Yeshiva University Inhibition of skp2-cyclin a interaction
EP1964560A1 (en) * 2007-02-28 2008-09-03 Helmholtz-Zentrum für Infektionsforschung GmbH Use of inhibitors of the degradation of p27 for the treatment of cancer
US20090054312A1 (en) * 2007-08-22 2009-02-26 Wolf Dieter A SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
EP2138507A1 (en) 2008-06-23 2009-12-30 Helmholtz-Zentrum für Infektionsforschung GmbH Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles
US10988759B2 (en) 2016-01-15 2021-04-27 University Of Washington High throughput protein-protein interaction screening in yeast liquid culture
US20220380754A1 (en) 2020-05-11 2022-12-01 A-Alpha Bio, Inc. High-Throughput Screening Methods to Identify Small Molecule Targets
AU2021285824B2 (en) 2020-06-01 2023-08-03 A-Alpha Bio, Inc. Methods for characterizing and engineering protein-protein interactions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012679A1 (en) * 1998-08-28 2000-03-09 New York University Novel ubiquitin ligases as therapeutic targets
WO2000075184A1 (en) * 1999-06-04 2000-12-14 Yale University Modulation of protein levels using the scf complex

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519003A (en) * 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US5981702A (en) * 1995-09-21 1999-11-09 Cold Spring Harbor Laboratory Cyclin/CDK associated proteins, and uses related thereto
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
JP2002517998A (en) * 1998-06-18 2002-06-25 キュラジェン コーポレイション Interaction of p27 (KIP1) with FKBP-12
US6638734B1 (en) * 1999-06-11 2003-10-28 The Burnham Institute Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012679A1 (en) * 1998-08-28 2000-03-09 New York University Novel ubiquitin ligases as therapeutic targets
WO2000075184A1 (en) * 1999-06-04 2000-12-14 Yale University Modulation of protein levels using the scf complex

Also Published As

Publication number Publication date
US20090104642A1 (en) 2009-04-23
US20050260556A1 (en) 2005-11-24
CA2433795A1 (en) 2002-07-18
ZA200305230B (en) 2004-07-07
US20050208601A1 (en) 2005-09-22
US20020123082A1 (en) 2002-09-05
US20050272066A1 (en) 2005-12-08
NZ527047A (en) 2006-09-29
US20050214879A1 (en) 2005-09-29
JP2004531218A (en) 2004-10-14
WO2002055665A2 (en) 2002-07-18
AU2002243477B2 (en) 2007-12-20
IL156778A0 (en) 2004-02-08
EP1352080A2 (en) 2003-10-15
US20090208973A1 (en) 2009-08-20
JP4121854B2 (en) 2008-07-23
EP1352080A4 (en) 2005-04-06

Similar Documents

Publication Publication Date Title
WO2002055665A3 (en) Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
WO2005005462A3 (en) Blys antagonists and uses thereof
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
SE0301010D0 (en) Novel compounds
SE0301009D0 (en) Novel compounds
NO20053114L (en) Asthma and allergic inflammatory modulators.
MXPA05012026A (en) Azaindole compounds as kinase inhibitors.
TW200519075A (en) Novel compounds
WO2003068746A8 (en) Aryl ureas as kinase inhibitors
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
SE0301373D0 (en) Novel compounds
WO2006017214A3 (en) Inhibitors of histone deacetylase
NO20070866L (en) Antiviral compounds.
EA200801372A1 (en) METHODS OF OBTAINING SUBSTITUTED PYRIMIDINES
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
HK1098471A1 (en) Azaindoles useful as inhibitors of jak and other protein kinases
UA86591C2 (en) Pyrrolodihydroisoquinolines as pde10 inhibitors, pharmaceutical composition based thereon
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
WO2007052023A3 (en) Novel compounds
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
UA96279C2 (en) Isolated antibody or fragment thereof that is capable of binding to human nogo
WO2006034391A3 (en) Indole inhibitors of 15-lipoxygenase
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71
WO2006113251A3 (en) Methods to identify compounds useful for the treatment of proliferative and differentiative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 156778

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002556716

Country of ref document: JP

Ref document number: 2433795

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/05230

Country of ref document: ZA

Ref document number: 200305230

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 527047

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002708966

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002243477

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002708966

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2002243477

Country of ref document: AU

Date of ref document: 20020107

Kind code of ref document: B